In a groundbreaking development for those battling pancreatic cancer, a new drug named daraxonrasib has demonstrated remarkable results in clinical trials. Patients with advanced pancreatic cancer, who previously had limited options, are seeing their survival time double with this new treatment.

Hope for Pancreatic Cancer Patients

The clinical trial, led by Dr. Zev Wainberg at UCLA Health, involved 500 patients and revealed that those taking daraxonrasib lived an average of 13.2 months compared to 6.7 months for those on chemotherapy. The drug targets a mutation in the KRAS gene, which is prevalent in over 90% of pancreatic cancers.

Dr. Rachna Shroff from the University of Arizona Cancer Center expressed her excitement about the drug’s potential, calling it a ‘game-changer’ for pancreatic cancer treatment. The FDA has fast-tracked the approval process, allowing Revolution Medicines to provide the drug to patients outside of clinical trials through an expanded access program.

Beyond Pancreatic Cancer

Daraxonrasib’s potential extends beyond pancreatic cancer, as it targets a mutation found in various other cancers, including lung and colorectal cancers. Dr. Brian Wolpin from Dana-Farber Cancer Institute believes this is just the beginning, with more applications for the drug likely to emerge.

While daraxonrasib is not a cure, it offers a significant improvement in quality of life with fewer side effects than traditional chemotherapy. Patients like Debby Orcutt, who has seen her tumors shrink significantly, are experiencing minimal side effects, such as mild rashes and sores.

As research continues, the hope is that daraxonrasib will lead to a new era of cancer treatment, providing patients with more effective and less toxic options.

Original reporting: NBC Connecticut — read the source article.